News Article | May 16, 2017
PARIS--(BUSINESS WIRE)--Voisin Consulting Life Sciences (VCLS) announces the appointment of Carole Jones as Director of Market Access. Ms Jones will focus on expanding the company’s Market Access capabilities, enhancing the variety of services that VCLS already offers. The company’s vision is to support clients to find creative solutions to funding issues and risk sharing strategies, and to manage uncertainty through robust evidence generation. Ms Jones’ responsibilities will span payer strategy, Health Economics and Outcomes Research (HEOR), Health Technology Assessment (HTA) and value communications support. Ms Jones’ extensive experience working directly with NICE and NIHR on HTAs and policy development, as well as her close relationships with various Clinical Commissioning Groups in the UK, Gemeinsamer Bundesausschuss (G-BA) and Haute Autorité de Santé (HAS) in Europe and the Centers for Medicare and Medicaid in the U.S., makes her ideally suited to this position. ‘We at VCLS, are excited about the appointment of Carole Jones and the opportunities it will bring. It further demonstrates our commitment to becoming leaders in product development and commercialization consultation, by offering a well-rounded service to our clients. The extensive experience Carole brings will strengthen our capabilities and put us at the forefront of integrated pharmaceutical development strategy.’ commented Emmanuelle Voisin, Founder and CEO, VCLS. Ms Jones brings with her a wealth of knowledge and experience from a variety of roles within the healthcare sector. Her career started in the clinical environment and she subsequently gained industry experience working in the commercialization team at QLT (now Novelion Therapeutics), the Canadian biotech company that brought a cutting edge, first-in-class age-related macular degeneration product to market in partnership with Novartis. Ms Jones then transitioned to a global consulting role in IMS Health (now QuintilesIMS) where she was promoted to Practice Leader of the Portfolio Strategy practice and managed the EMEA region for 6 years. Since leaving IMS, Ms Jones has led the Market Access Solutions practice at Envision Pharma Group, a medical affairs company, where she was involved in publication strategy, development of manuscripts and white papers for peer-reviewed journals, systematic literature reviews, global value dossiers and interactive field-based assets. ‘I am delighted to be part of an organization with such an active focus on the integration of payer evidence requirements into the clinical development programs of our clients. The combination of world class regulatory and health economics expertise allows us to be powerful advocates for our clients in navigating the complex, evolving pharmaceutical environment. The goal of delivering innovative therapies and making them accessible to patients is at the forefront of the company’s, and my own, vision.’ said Ms Jones. Market access has become all the more critical as payer constraints grow. The development of an evidence-based strategy with an expanded value proposition that meets the needs of multiple stakeholders, including patients, is essential to the success of new entrants, never more so than in the area of Advanced Therapy Medicinal Products (ATMPs) where many of our clients are active. Ms Jones will be presenting a poster on overcoming the challenges of establishing expanded access programs in European member states at the ISPOR annual meeting to be held in Boston in May, 2017 and writes extensively on the topic of access for first-in-class innovative molecules. About Voisin Consulting Life Sciences Voisin Consulting Life Sciences is a global product development consultancy, which guides Biotechnology, Pharmaceutical and Medtech manufacturers throughout product development and commercialization. From discovery to patients, VCLS assists innovators to design product development strategies that optimize clinical development in order to drive commercial success, through an understanding of both regulators and providers of healthcare. VCLS’s team of health product specialists seamlessly supplement innovative life sciences companies’ resources with strategic advice and cross-functional operational capabilities. The firm offers integrated solutions to development planning, manufacturing, quality and controls, nonclinical and clinical testing, safety monitoring, and interactions with regulators and health technology assessment agencies. With offices in Cambridge, Somerville and San Francisco (MA, CA & NJ, USA), London (UK), Paris and Rennes (France), Lausanne (Switzerland) and Bangalore (India), VCLS serves a broad range of developers and investors.
News Article | May 18, 2017
Chicago, Illinois-based Ventas Inc.'s stock finished Wednesday's session 2.00% higher at $66.32. A total volume of 2.74 million shares was traded, which was above their three months average volume of 2.02 million shares. The Company's shares have advanced 8.82% in the previous three months and 7.36% since the start of this year. The stock is trading 4.17% above its 50-day moving average and 3.51% above its 200-day moving average. Additionally, shares of Ventas, which engages in investment, management, financing, and leasing of properties in the healthcare industry, have a Relative Strength Index (RSI) of 64.20. VTR complete research report is just a click away and free at: On Wednesday, shares in Newton, Massachusetts-based Senior Housing Properties Trust recorded a trading volume of 2.23 million shares, which was above their three months average volume of 1.92 million shares. The stock ended the session 0.05% higher at $20.93. The Company's shares have advanced 7.17% in the previous three months and 10.57% on an YTD basis. The stock is trading 0.59% above its 50-day moving average and 2.57% above its 200-day moving average. Moreover, shares of Senior Housing Properties Trust, which invests in senior housing properties in the US, have an RSI of 47.81. On May 15th, 2017, research firm RBC Capital Markets downgraded the Company's stock rating from 'Outperform' to 'Sector Perform' while revising its previous target price from $24 a share to $22 a share. The complimentary report on SNH can be downloaded at: Scottsdale, Arizona-based Healthcare Trust of America Inc.'s shares closed the day 0.03% higher at $30.93. The stock recorded a trading volume of 3.38 million shares, which was higher than its three months average volume of 2.06 million shares. The Company's shares have gained 4.68% over the previous three months and 8.31% on an YTD basis. The stock is trading 2.67% above its 200-day moving average. Additionally, shares of Healthcare Trust of America, which engages in acquiring, owning and operating high-quality medical office buildings located primarily on-campus or affiliated with the nation's leading healthcare systems, have an RSI of 51.44. Sign up for your complimentary research report on HTA at: Shares in Quality Care Properties Inc. finished 0.57% lower at $17.46. The stock recorded a trading volume of 525,718 shares. The Company's shares have advanced 12.65% on an YTD basis. The stock is trading above its 200-day moving average by 3.02%. Furthermore, shares of Quality Care Properties, which operates independently of HCP, Inc. as of October 31, 2016, have an RSI of 43.30. Get free access to your research report on QCP at: Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. SC has not been compensated; directly or indirectly; for producing or publishing this document. The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way. SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: firstname.lastname@example.org Phone number: +44-330-808-3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
News Article | May 19, 2017
The demand from regulators and payers for health economic models is increasing, as these key decision makers struggle to manage budget constraints and provide access to new therapies TORONTO, ON--(Marketwired - May 19, 2017) - On Wednesday, June 7, 2017, Victoria Paly, MHS, Senior Health Economist and Dhvani Shah, MS, Lead Health Economist, both from ICON, will provide insight about using early economic modelling to better reflect the evolution of new therapies. This will in turn enhance the commercialisation of these therapies, and effectively communicate the value of these therapies to all key decision makers. Health economic models are required to demonstrate product value and support reimbursement submissions; however, early economic models (EEMs) can also be used to inform clinical development decisions, develop HEOR and real-world evidence (RWE) generation planning and support early pricing and market access discussions. Join the presenters to learn best practices for developing early economic models to inform key strategic decisions. Through discussion and a case study, get insights on: Healthcare decision makers around the world are increasingly requiring information on cost-effectiveness of new therapies as they struggle for ways to manage their budgets while providing access. Such cost-effectiveness evaluations generally require Phase III clinical data and are conducted at the time of product launch. However, conducting such evaluations early in the clinical development process can identify gaps in evidence, help in internal pricing discussions, inform clinical trial development decisions, inform RWE generation planning and identify which parameters are most influential to reimbursement decisions. The lack of certainty between the data at launch and a drug's ongoing clinical performance expectations are key clinical and reimbursement concerns for both HTA reviewers and the payers they influence. Early modelling can help to fill the gap between the data currently available and the expected long-term clinical, economic, and humanistic outcomes. To learn more about this free webinar visit: Using Early Economic Models in Developing your Evidence Strategy Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global Life Sciences community. Every year thousands of industry practitioners (from pharmaceutical & biotech companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers. To learn more about Xtalks visit http://xtalks.com For information about hosting a webinar visit http://xtalks.com/sponsorship.ashx
News Article | May 24, 2017
Live session on June 8, 2017 features expert panel from INC Research discussing the why, where, when and how a rare disease drug is intended to be used subsequent to approval and the importance of beginning with the end in mind TORONTO, ON--(Marketwired - May 24, 2017) - Interest in the development of medicines to alleviate or cure rare diseases has increased due to (1) positive actions taken by global regulatory agencies; (2) advances in the understanding of disease pathophysiology; and (3) tools, such as exome and whole-genome sequencing, to produce more efficacious drugs. With rare diseases, the clinical data needed to support HTA or health insurer assessments are often weak because of the scarcity of study subjects. It is, therefore, essential to establish a robust integrated medical plan for drugs in development that clearly sets out not only the core development data required to prove safety and efficacy but also ensures that other evidence gaps are addressed. To best achieve this, a clear understanding of why, where, when and how the drug will be used after approval is needed - Quite literally 'begin with the end in mind'. Such a holistic approach will ensure a streamlined, evidence-based development process that maximizes post-approval activities matched to capture the full potential of the product. By anticipating the possible hurdles for the approval and reimbursement of any new rare disease treatment will ultimately lead to earlier access to those patients who may benefit due to a high unmet medical need. The objectives are to: Upon completion of this webinar, the attendee should be able to: For more information or to register for this free event visit: The Good, the Bad, the Necessary in Rare Disease Studies Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global Life Sciences community. Every year thousands of industry practitioners (from pharmaceutical & biotech companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers. To learn more about Xtalks visit http://xtalks.com
News Article | May 22, 2017
NEW YORK (Reuters) - Puerto Rico's federal oversight board has sought bankruptcy protection for the island's highway authority and largest public pension, making them the latest commonwealth entities to turn to a court to work out debt. The board filed the cases late on Sunday in U.S. District Court in San Juan, under a process akin to U.S. bankruptcy, known as Title III, that was created by the U.S Congress last year. Puerto Rico's central government, as well as its COFINA sales tax authority, are already in Title III bankruptcy, and a lawyer for the oversight board said last week other agencies would follow "soon." The latest filings could set the stage for an unconventional fight between retirees and the very lenders whose money was supposed to sustain them, an indication of just how complex Puerto Rico's debt structure is. The island has $70 billion in public debt, a 45 percent poverty rate and unemployment more than twice the U.S. average. Its pensions owe another $50 billion to retirees who may face benefit cuts as part of Puerto Rico's restructuring. The pension in Title III bankruptcy, known as ERS, is unique in that it also owes $3.1 billion in bond debt, the result of an ill-fated financing effort in 2008 that was meant to plug its growing funding gap. The structure of the bonds, which gives holders a lien on employer pension contributions, is exceedingly rare, and means bondholders may be battling with retirees for recoveries. ERS was on track to deplete its reserves this month, potentially triggering a default, Moody's Investors Service said in February. A committee of pension bondholders, led by hedge funds Claren Road and Altair, sued Puerto Rico last fall to try to protect their lien, but the case is sidelined while the debt restructuring plays out. Highway authority HTA owes some $6 billion in debt - including more than $46 million to Puerto Rico's power utility, PREPA, according to the court filing. It was not immediately clear whether the new Title III cases would be combined with the central government's case. Last week, Judge Laura Taylor Swain ruled that the central government and COFINA cases would be combined for administrative purposes.
News Article | May 4, 2017
BURLINGTON, Mass., May 4, 2017 /PRNewswire/ -- A novel web-based interactive 3-dimensional (3-D) tool has been developed by Decision Resources Group Abacus in collaboration with leading academics at Leicester University to facilitate the visualisation and exploration of covariate distributions and imbalances across evidence networks for network meta-analysis (NMA). Network meta-analysis is becoming increasingly important for decision makers to assess the comparative efficacy and safety of interventions and is integral to health technology assessment (HTA). The exploration of covariate effects is important in NMA because the presence of unaccounted treatment covariate interactions can invalidate the assumptions that underlie NMA and bias results. Visually assimilating, exploring and interpreting the distribution of covariate values across trials in an NMA is challenging due to the complexities of representing the network structure alongside study-level covariate values.
News Article | April 17, 2017
OAKVILLE, ONTARIO--(Marketwired - April 17, 2017) - Tech Achievers Growth & Income Fund (TSX:HTA.UN) (the "Fund") announce that the special meeting of the Fund (the "Meeting") scheduled for Monday, April 17, 2017 has been adjourned to Friday, April 28, 2017. Instead of converting the Fund into a conventional unlisted mutual fund on or about June 20, 2017 as originally contemplated, at the Adjourned Meeting, unitholders of the Fund will be asked to approve the conversion of the Fund from a closed-end fund into class A units of an exchange-traded fund (the "Conversion"), including a reduction in the Fund's annual management fee to 0.85% (from 1.00%). The notice of meeting, management information circular and related Meeting materials, which detail the matters to be considered at the Meeting, are available at www.sedar.com. The management information circular is also available on the Fund's website at www.harvestportfolios.com. You will usually pay brokerage fees to your dealer if you purchase or sell units of the Fund(s) on the TSX. If the units are purchased or sold on the TSX, investors may pay more than the current net asset value when buying units of the Fund(s) and may receive less than the current net asset value when selling them. There are ongoing fees and expenses associated with owning units of an investment fund. Investment funds are not guaranteed, their values change frequently and past performance may not be repeated. An investment fund must prepare disclosure documents that contain key information about the fund. You can find more detailed information about the fund in these documents. The information contained herein is not an offer to sell nor a solicitation to buy any security. Such an offer can only be made by prospectus or other applicable offering document.
News Article | April 28, 2017
OAKVILLE, ONTARIO--(Marketwired - April 28, 2017) - Tech Achievers Growth & Income Fund (TSX:HTA.UN) (the "Fund") announces that at the special meeting held today, unitholders approved the conversion of the Fund from a closed-end fund into an exchange-traded fund (the "Conversion"). Instead of converting the Fund into a conventional unlisted mutual fund on or about June 20, 2017 as originally contemplated, at the special meeting, unitholders of the Fund approved the conversion of the Fund from a closed-end fund into class A units of an exchange-traded fund (the "Conversion"), including a reduction in the Fund's annual management fee to 0.85% (from 1.00%). The Manager anticipates implementing the Conversion in June, 2017, subject to obtaining a receipt for the final prospectus of the exchange traded fund and any necessary third party or regulatory approvals. The Manager will issue a press release confirming the effective date of the Conversion after the required approvals have been obtained. Details of the special meeting are further described in the management information circular which is available at www.sedar.com. The management information circular is also available on the Fund's website at www.harvestportfolios.com. You will usually pay brokerage fees to your dealer if you purchase or sell units of the Fund(s) on the TSX. If the units are purchased or sold on the TSX, investors may pay more than the current net asset value when buying units of the Fund(s) and may receive less than the current net asset value when selling them. There are ongoing fees and expenses associated with owning units of an investment fund. Investment funds are not guaranteed, their values change frequently and past performance may not be repeated. An investment fund must prepare disclosure documents that contain key information about the fund. You can find more detailed information about the fund in these documents. The information contained herein is not an offer to sell nor a solicitation to buy any security. Such an offer can only be made by prospectus or other applicable offering document.
News Article | May 5, 2017
I know that it has been almost three years since Windows 10 first came on the scene, but as you may recall the first iteration of the operating system was pretty bland when it came to color. In fact, the only color in the title bars was white. That was frustrating for the mere fact that we've been able to change the color of title bars ever since Windows 3.x—but having only white title bars also made it difficult to distinguish between active and inactive windows. Within five months of the initial release, Microsoft released the Windows 10 November Update, which, among other things, included the capability to set the color of the active title bar. (For a look back, check out my December 2015 article The Windows 10 November Update: A look at the smaller details.) While being able to once again set the color of active title bars made it easier to distinguish between active and inactive windows, it would have been nice to be able to set the color of inactive title bars as well. Unfortunately, Microsoft never completely brought back that feature. It did, however; leave some codes in the registry you could use to add color to inactive title bars. To make it easy to access those registry codes, I created a little HTML application, which I presented in a July 2016 article titled Colorize the Windows 10 inactive title bar with this handy HTA. If like me you have been longing for more control over the colors in Windows 10's user interface, you'll be happy to learn more about the new colorization features Microsoft has bestowed upon the operating system in the Creators Update. Let's take look. The new colorizing features are of course found on the Colors tab, which you can quickly access by pressing Windows+I to bring up the Windows Settings window, typing Color, and clicking Color settings, as shown in Figure A. When you see the Colors tab, shown in Figure B, you'll notice that Microsoft has simplified and reorganized the layout. You can still have Windows automatically pick an accent color based on your background color, pick one of the colors in the default color palette, enable transparency, and choose which UI components to colorize. You can also choose the Light or Dark setting for certain apps. Just below the color palette, you'll see the Custom Color button. Clicking it brings up the Choose A Custom Accent Color dialog, where you can use the various controls to select a custom color. Creating a custom accent color is an interesting endeavor. To see how this works, let's begin by picking a color from the default color palette. For example, choose Red and click the Custom Color button. When the Choose A Custom Accent Color dialog appears, you can see the color is targeted on Red, as indicated by the circle in the upper-right corner of the color field and the tool tip, as shown in Figure C. The bar on the right also shows the selected color. The Color Preview boxes show you how the color will appear in the user interface. The slider on the bottom of the color field allows you to adjust the value of the selected color. Value is defined as the relative lightness or darkness of a color. Sliding to the right increases the value, making the color lighter. Sliding to the left decreases the value, making the color darker. As you move the slider, you'll see a tool tip appear above the slider that displays the value and the color. When you have a dark color selected, as you decrease the value you'll reach a point where the color is too dark and you'll see this message appear below the Color Preview boxes: This color is not supported. As you adjust the value, the top half of the bar on the right of the palette will change to match the color value, while the bottom of the bar will stay the original color. All these items are shown in Figure D. In addition to adjusting the value, you can change the color by clicking and dragging the targeting circle to different locations on the color field. When you have a light color selected and you increase the value, you'll reach a point where the color is getting too light. At that point, you'll see the message This color looks like it might be hard to read. Figure E shows these items. If you continue to increase the value, you'll reach a color that is not supported. If you click the More down arrow, you can choose and customize your colors using Hexadecimal color codes, RGB values, or HSV (Hue, Saturation, Value) values, as shown in Figure F. This makes it easy to get the exact color you want if you already know the Hexadecimal code number or the series of RGB or HSV values. It also works the other way around: You can move the targeting circle to different locations on the color field or adjust the value slider. As you do, the numbers in the Hexadecimal, RGB, or HSV fields will change. In addition to choosing a custom accent color, you can choose a custom background color. When you are finished choosing your custom accent color, select the Background tab. Select Solid Color from the Background dropdown and you'll see a Custom Color button just below the color palette, as shown in Figure G. Now, choosing a custom color for your desktop background works just like choosing your accent color. What do you think of the new colorizing features in the Windows 10 Creators Update? Share your thoughts with fellow TechRepublic members.
News Article | May 4, 2017
Network meta-analysis is becoming increasingly important for decision makers to assess the comparative efficacy and safety of interventions and is integral to health technology assessment (HTA). The exploration of covariate effects is important in NMA because the presence of unaccounted treatment covariate interactions can invalidate the assumptions that underlie NMA and bias results. Visually assimilating, exploring and interpreting the distribution of covariate values across trials in an NMA is challenging due to the complexities of representing the network structure alongside study-level covariate values. In a recently published paper in the Journal of Clinical Epidemiology, DRG Abacus and Leicester University outline the rationale for and the features of the software tool and present a series of illustrative examples. For more information contact our Systematic Review team at Access@TeamDRG.com Follow DRG on Twitter @DRGInsights and on LinkedIn and keep up with the latest industry news on the DRG Blog. About Decision Resources Group DRG, a subsidiary of Piramal Enterprises Ltd., offers best-in-class, high-value data, analytics and insights products and services to the healthcare industry, delivered by more than 1000 employees across 17 offices in North America, Europe and Asia. DRG provides the Life Sciences, Provider, Payer and Financial Services industries the data, tools, insights and advice they need to compete and thrive in an increasingly complex and value-based marketplace. decisionresourcesgroup.com.